Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
(By Arthur Allen for KFF Health News) This week the FDA is expected to approve what many scientists and doctors
Read More
FDA
An Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why
(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval
Read MoreTransforming Medicare Coverage: A New Medicare Coverage Pathway for Emerging Technologies and Revamped Evidence Development Framework
(Source – www.cms.gov) The Centers for Medicare & Medicaid Services (CMS) is committed to fostering innovation while ensuring that people
Read MoreDrugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
(By Arthur Allen for KFF Health News) On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant
Read MoreSome cancer drugs are in short supply, putting patients’ care at risk. Here’s why
(By Yuki Noguchi for NPR) Toni Dezomits is used to facing death. She served in the Gulf War and later
Read MoreFDA approves Pfizer’s RSV vaccine for older adults
(By Helen Branswell for STAT) The Food and Drug Administration approved a second vaccine to protect older adults against RSV
Read MoreScience finally figured out how to make effective RSV vaccines. Will seniors care?
(By Helen Branswell for STAT) The world has waited decades for vaccines to protect older adults against RSV. One, made
Read MoreHow Medicare’s Aduhelm decision revived old questions about new drugs
(By Kerry Dooley Young for STAT) Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and Drug Administration’s
Read MoreNew Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare
(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published May 18, 2023) The FDA’s accelerated approval of Aduhelm
Read MorePBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention
(By Arthur Allen for KFF Health News) For two decades, patients and physicians eagerly awaited a lower-cost version of the
Read More